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Leptin plays a central role in maintaining energy balance, with multiple other systemic effects. Despite leptin
importance in peripheral regulation of mesenchymal stem cells (MSC) differentiation, little is known about its
expression mechanism. Leptin is often described as adipokine, while it is expressed by other cell types. We have
recently shown an in vitro leptin expression, enhanced by glucocorticoids in synovial fibroblasts (SVF). Here, we
investigated leptin expression in MSC from bone marrow (BM-MSC) and umbilical cord matrix (UMSC). Results
showed that BM-MSC, but not UMSC, expressed leptin that was strongly enhanced by glucocorticoids.
Transforming growth factor b1 (TGF-b1) markedly inhibited the endogenous- and glucocorticoid-induced leptin
expression in BM-MSC. Since TGF-b1 was shown to signal via ALK-5-Smad2/3 and/or ALK-1-Smad1/5
pathways, we analyzed the expression of proteins from both pathways. In BM-MSC, TGF-b1 increased phos-
phorylated Smad2 (p-Smad2) expression, while ALK-5 inhibitor (SB431542) induced leptin expression and
significantly restored TGF-b1-induced leptin inhibition. In addition, both prednisolone and SB431542 increased
p-Smad1/5 expression. These results suggested the ALK-5-Smad2 pathway as an inhibitor of leptin expression,
while ALK-1-Smad1/5 as an activator. Indeed, Smad1 expression silencing induced leptin expression inhibition.
Furthermore, prednisolone enhanced the expression of TGF-bRII while decreasing p-Smad2 in BM-MSC and
SVF but not in UMSC. In vitro differentiation revealed differential osteogenic potential in SVF, BM-MSC, and
UMSC that was correlated to their leptin expression potential. Our results suggest that ALK-1/ALK-5 balance
regulates leptin expression in MSC. It also underlines UMSC as leptin nonproducer MSC for cell therapy
protocols where leptin expression is not suitable.
Introduction
Leptin is a nonglycosylated peptide hormone that playsa crucial role in regulating central energy balance, and
controlling appetite in humans. In addition, it has been shown
that leptin plays a role in regulating bone mass through os-
teogenic differentiation of mesenchymal progenitor cells [1,2].
Despite the fact that it was discovered in 1994, progress in
understanding mechanisms of leptin expression has been
slowed by the lack of cell lines that express leptin and respond
robustly to hormonal signals [3]. Leptinwaswidely studied in
3T3-L1 mouse cell line described as having the potential to
differentiate into adipocytes, but with a low level of leptin
mRNA expression [4,5]. The transcriptional regulation of the
leptin gene was described as being controlled by Peroxisome
proliferator-activated receptor-gamma (PPAR-g) [6–8], and
down-regulated by adrenergic stimulation [9]. Although de-
scribed as an adipocyte-derived hormone, leptin is also se-
creted by several other cell types [7,10]. We have recently
shown an in vitro leptin expression that was enhanced by
glucocorticoids in mesenchymal synovial fibroblasts (SVF)
[11]. Single or repeated injections of glucocorticoids were also
shown to elevate rat plasma leptin in a dose-dependent
manner [12]. On the other hand, leptin receptor expression
was decreased in vitro in human bronchial epithelial cells by
transforming growth factor b1 (TGF-b1) [13]. Despite these
results, no mechanism of leptin expression has been pro-
posed. In this study, we investigated leptin expression in bone
marrow-derived mesenchymal stem cells (BM-MSC) that are
widely used in various cell therapy protocols, and in umbilical
cord matrix-derived MSCs (UMSC) that are considered as an
emerging source of MSC for cell therapy [14]. Results
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demonstrated that BM-MSC but not UMSC produced leptin.
We also showed that glucocorticoids and TGF-b1 can regulate
leptin expression through ALK-1-Smad1/5 and ALK-5-
Smad2/pathways.
Materials and Methods
Isolation and culture of MSC
Processing of umbilical cord samples and subsequent
isolation of UMSC (n= 9) from human umbilical cord were
achieved as described in Ref. [15]. BM was obtained from
iliac crest marrow aspiration of healthy donors after in-
formed consent. Isolation of BM MSCs (n = 7) was performed
as described in Ref. [14]. The synovial tissue were obtained
from patients during joint replacement. Informed consents
were obtained, and experiments were approved by the ethics
committee of our academic hospital (CHU, Lie`ge, Belgium).
SVF (n = 10) were isolated as previously explained [16,17].
MSC were cultured in a complete medium consisting of
Dulbecco’s modified Eagle’s medium (DMEM) medium
(Cambrex Bio Science), with l-glutamine (2mM), strepta-
mycin (100mg/mL), and penicillin (100U/mL) (BioWhit-
taker), and supplemented with 10% fetal bovine serum (FBS)
(Lonza). Cells (5 · 104 cells/0.5mL of medium) were seeded
in 24-well plates (BD Biosciences) in triplicate. On the second
day of culture, cells were stimulated with prednisolone, TGF-
b (GIBCO-BRL), or SB 431542 (Sigma-Aldrich). After 1 week,
the medium was collected for enzyme-linked immunosor-
bent assay (ELISA) tests, and cells were harvested for protein
extraction.
Enzyme-linked immunosorbent assay
Leptin concentrations were determined in the cell super-
natant using a commercial kit (R&D Systems) according to
the manufacturer’s instructions.
Transfection with lentivirus expressing
Smad1 shRNA
SVF were plated at a density of 5 · 103 cells/cm2 in 6-well
plates and cultured overnight in complete medium (day 0).
At day 1, the medium was replaced by a mixture of complete
medium with polybrene (6 mg/mL) (sc-134220). Infection
was performed by adding 15mL of the pool of Smad1 shRNA
(sc-29483) or control shRNA (sc-108080) infecting lentivirus
(Santa Cruz Biotechnology). After over-night incubation
with lentivirus, the medium was replaced, and the cells were
incubated for 24 h. Selection of the cells was performed with
2 mg/mL of puromycin (P7255) (Sigma-Aldrich) for 48 h.
Western blot
Cells were collected and lysed, and total were proteins
separated by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis as explained earlier in Ref. [16]. Membranes were
incubated with TGFb-RI (#3712), Smad1 (#9743), phosphory-
lated Smad1 (p-Smad)1/5 (#9516), p-Smad2 (S465/467)
(#3101), Smad2 (L16D3) (#3103), (Cell Signaling), ALK-1 (H-
150) (sc-28976), TGFb-RII (C-16) (sc-220), OB-R (B-3) (sc-8391),
ERK1/2 (K-23) (sc-94), Runx-2 (27-K) (Sc-101145) (Santa Cruz
Biotechnology), and a-Tubulin (T6074) (Sigma-Aldrich) anti-
bodies for 1–3h at room temperature. Western blots were
shown with 1:2,000 diluted anti-mouse or anti-rabbit (DAKO
A/S) antibodies and ECL chemiluminescent reagents (Amer-
sham Biosciences). Bands intensities were quantified using
Quantity one 4.6.5 software (Bio-Rad Laboratories, Inc.). Re-
lative quantifications represent the mean– standard deviation
of 3 different experiments performed on 3 different donors. The
Mann–Whitney test was used to calculate significant differ-
ences between conditions.
Osteogenic differentiation
To induce osteogenic differentiation, 3· 103 cells/cm2
were plated in DMEM supplemented with 10% FBS, 10mM
b-glycerophosphate, 60mM ascorbic acid, and 10 - 7 M dexa-
methasone (Sigma Aldrich), and cultured for 3–4 weeks.
Medium was replaced every 3–4 days. The induction of al-
kaline phosphatase (ALP) expression was detected after 3
weeks using histochemical staining assays. Briefly, cells were
fixed with 70% (v/v) ethanol (Sigma-Aldrich) at room tem-
perature for 10min. After being washed with phosphate-
buffered saline solution, cells were stained using a mixture of
0.3mg/mL naphthol AS-MX phosphate, 0.005mg/mL of
NN dimethylformamide in Tris buffer (0.2M, pH 9.1), and
1mg/mL fast blue BB salt (Sigma-Aldrich).
Microscopy
Photos were captured using a digital sight camera (2MV)
under the inverted microscope Eclipse TS100 (Nikon In-
struments, Inc.), using NIS-Elements Basic Research software
(Nikon Instruments, Inc.) and objectives with phase contrast.
Statistics
P values were obtained using the Mann–Whitney U-test
and were considered significant when < 0.05.
Results
BM-MSC are robust leptin producers, while UMSC
do not express leptin
BM-MSC and UMSC were cultured for 7 days in the
presence or absence of the glucocorticoid prednisolone. SVF,
which we have recently shown to be leptin producers [11],
were used as a positive control. ELISA analysis showed that
BM-MSC expressed leptin, and that this expression was
markedly up regulated by prednisolone (10 - 6 M) treatment
(Fig. 1). In contrast, no leptin production was detected in
UMSC cultures in the absence or presence of prednisolone
(Fig. 1). The effect of glucocorticoids (prednisolone or dexa-
methasone) on BM-MSC and SVF was clearly dose depen-
dent (10 - 9 to 10 - 6 M), with leptin expression reaching a
plateau for a concentration of prednisolone around 10 - 6 M
(data not shown).
SB 431542, a specific ALK-5 inhibitor, increased
leptin expression and restored TGF-b-inhibited
leptin expression in BM-MSC
Searching for the signalling pathways involved in MSC
leptin expression, we observed that TGFb1 is an inhibitor of
leptin expression in both SVF (data not shown) and BM-MSC
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(Fig. 2A). TGF-b1 was shown to signal via ALK-1 (Smad1/5
pathway) and/or ALK-5 (Smad2/3 pathway) [18]. To in-
vestigate these pathways, we treated BM-MSC with an
ALK-5 inhibitor (SB 431542) in the presence or absence of
prednisolone and TGF-b1 (Fig. 2A). ELISA analysis showed
that TGF-b1 significantly inhibited both endogenous and
glucocorticoid-induced leptin expression. The inhibition of
leptin expression observed by TGF-b1 was partially blocked
in the presence of SB 431542 (Fig. 2A). This effect was asso-
ciated with increased p-Smad-1/5 expression (Fig. 2A). SB
431542 alone induced leptin expression in BM-MSC (Fig. 2A)
but not in UMSC (data not shown), suggesting that the ALK-
5/Smad2 pathway may not be the only leptin repressing
pathway in these cells. The effect of SB 431542 was dose
dependent (0.5–10mM), with leptin expression reaching a
plateau for a concentration of SB 431542 around 10mM (data
not shown).
We also tested the effect of glucocorticoids, TGF-b1 and SB
431542 on leptin receptor (OB-R) expression in BM-MSC and
FIG. 1. Bone marrow-derived stem cells BM-MSC and sy-
novial fibroblasts (SVF), but not umbilical cord matrix-
derived stem cells (UMSC), produce leptin. BM-MSC (n= 7),
UMSC (n= 9) and SVF (n > 10) were cultured in the presence
or absence of prednisolone for 7 days. Leptin production was
measured in the culture supernatant by enzyme-linked im-
munosorbent assay (ELISA). *b, statistically different from a
and d. *d, statistically different from c. Results are shown as
the average of 3 representative experiments.
FIG. 2. SB 431542, an ALK-5 inhibitor, induces leptin
expression and restores transforming growth factor b (TGF-
b)-inhibited leptin expression in BM-MSC. BM-MSC (n= 4)
were cultured for 7 days in the presence or absence of
prednisolone, TGF-b1, and/or SB431542 at the indicated
concentrations. (A) Leptin was determined by ELISA in the
culture supernatants, and phosphorylated Smad2 (p-Smad2),
Smad2, p-Smad1/5, Smad1, and a-tubulin expressions were
detected by western blot. *a, statistically different from
control. *b, statistically different from prednisolone-treated
cells. *c, statistically different from prednisolone and TGF-b-
treated cells. (B) Western blot showing leptin receptor ex-
pression (OB-R) in BM-MSC cultured for 7 days in the
presence of prednisolone, TGF-b1, and/or SB431542 at the
indicated concentrations. (C) Leptin (ELISA) and Smad1
expression (western blot) in SVF transduced or not with
lentiviral particles for ShRNA of Smad1. *a, statistically dif-
ferent from b.
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found that OB-R expression was enhanced by prednisolone
(Fig. 2B). TGF-b1 inhibited endogenous and prednisolone
induced OB-R expression. Of interest, SB 431542 also in-
duced up-regulation of OB-R expression and partially re-
stored TGF-b1-induced OB-R expression inhibition (Fig. 2B).
These results suggested that the TGF-b pathway, through
ALK-5-Smad2/3 and ALK-1-Smad1/5 routes, may be in-
volved in negative and positive leptin expression regulation,
respectively.
Smad1 silencing inhibits leptin expression in MSCs
To further test the involvement of Smad1 in MSCs leptin
expression, we used lentiviral particles expressing Smad1
shRNA to infect SVF cells. Western blot analysis demon-
strated a significant decrease of Smad1 expression in infected
cells (Fig. 2C). ELISA analysis showed that Smad1 silencing
resulted in significant decrease in leptin expression (Fig. 2C).
No significant difference in leptin expression was observed
when we used lentiviral particles for the expression of con-
trol shRNA. These results further suggested that Smad1 is
involved in positive leptin expression regulation.
TGF-bRII and p-Smad-2 expression are modulated
by prednisolone in BM-MSC and SVF but not
in UMSC
We demonstrated that prednisolone significantly in-
creased leptin expression in SVF and BM-MSC but not in
UMSC. Thus, the effect of prednisolone on TGF-bRII and
p-Smad-2 expression was determined in BM-MSC, UMSC,
and SVF protein extracts (Fig. 3). Western blotting analysis
showed that prednisolone increased TGF-bRII and decreased
p-Smad2 expression in BMSC and SVF but not in UMSC. Of
interest, SVF, which are the most robust leptin producers,
had the lowest p-Smad2 expression level and showed the
highest TGF-bRII expression increase in the presence of
prednisolone. These results suggested that down-regulation
of Smad2 phosphorylation may be associated to leptin ex-
pression in BM-MSC as well as in SVF.
Differential osteogenic potential in SVF,
BM-MSC, and UMSC
Leptin was shown to be implicated in osteogenic differ-
entiation [1,2]. We, therefore, tested SVF, BM-MSC, and
UMSC for their osteogenic differentiation potential. SVF,
BM-MSC, and UMSC, cultured in DMEM + 10% FBS (con-
trol) or in osteogenic medium for 3 weeks, were tested for
ALP activity and Runx-2 expression (Fig. 4A, B, respective-
ly). In parallel, leptin expression was measured in culture
supernatants (Fig. 4C). ALP activity analysis revealed an
important staining with SVF that was increased in osteogenic
conditions. A less important ALP activity was detected with
BM-MSC, whereas no detectable ALP activity was observed
with UMSC (Fig. 4A). UMSC osteogenic differentiation for
longer than 3 weeks led to barely detectable ALP activity
(data not shown). Western blot analysis showed an obvious
up-regulation of Runx-2 expression in SVF in the presence of
osteogenic medium (Fig. 4B). Less Runx-2 expression was
detected in BM-MSC, whereas barely detectable Runx-2 ex-
pression was detected in UMSC in the presence or absence of
osteogenic medium (Fig. 4B). A higher level of leptin was
detected in osteogenic medium with SVF than with BM-
MSC, whereas no leptin expression was detected in osteo-
genic medium with UMSC (Fig. 4C). BM-MSC cultured in
osteogenic medium, in the absence of dexamethasone,
showed a significantly lower leptin expression level, and
decreased ALP activity (Fig. 4D). This suggests that one of
the roles of glucocorticoids (dexamethasone) in osteogenic
mixture may be to enhance leptin expression.
Discussion
Although it is known that leptin expression is modulated
by glucocorticoids in vitro and in vivo [12,19], very little is
known about the mechanisms involved. Leptin was widely
studied in 3T3-L1 mouse cell line described to have the po-
tential to differentiate into adipocytes but with a low level of
leptin mRNA expression [4]. Thus, recently, the need for a
cell model that expresses leptin and robustly responds to
hormonal signals for the study of leptin expression has
emerged [3]. Our earlier study showed that SVF, belonging
to mesenchymal lineages, expresses leptin, which is strongly
enhanced by glucocorticoids [11]. Here, we have shown that
BM-MSC, another MSCs, also expressed a basal level of
leptin that was markedly enhanced by glucocorticoids. Sur-
prisingly, UMSC did not express leptin. In an attempt to
understand the pathways involved in leptin expression, we
investigated TGFb1 pathways, as we observed that TGFb1
had an inhibitory effect on leptin expression in SVF (data not
shown) and BM-MSC (this work). We showed that leptin
expression parallels ALK-5 and p-Smad2 down-regulation as
well as the gain of ALK-1 and p-Smad1/5 expression. It was
previously reported that in addition to the well-characterized
ALK-5-Smad2/3 route, TGF-b1 can also signal via the
FIG. 3. Prednisolone up-regulates TGF-bRII and down-
regulates p-Smad2 expression in SVF and BM-MSC but not
in UMSC. BM-MSC (n= 4), UMSC (n = 4), and SVF (n = 4)
were cultured in the presence or absence of prednisolone for
7 days. Western blot shows TGF-bRII, p-Smad2, Smad2, and
a-tubulin expression in protein extracts from each culture. *a,
*b, *c, and *d: prednisolone stimulated statistically different
from control.
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alternative receptor ALK-1, resulting in Smad1/5 pathway
activation [18]. According to our results, we postulated that
ALK-5-Smad2 pathway inhibits leptin expression, whereas
ALK-1-Smad1/5 may function as an activator. Indeed, when
we compared p-Smad2 expression between different MSC
types, we found the highest level of p-Smad2 expression in
UMSC that do not express leptin, and the lowest p-Smad2
level in SVF that are robust leptin producers. In BM-MSC,
TGF-b1 induced p-Smad2 expression and markedly inhibited
leptin expression. These results supported the hypothesis
FIG. 4. Osteogenic differentiation capacity of UMSC, BM-MSC, and SVF. UMSC, BM-MSC, and SVF (n= 3) were exposed in
vitro to control [Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS)] or oste-
ogenic (DMEM supplemented with 10% FBS+ 10mM b-glycerophosphate, 60 mM ascorbic acid, and 10 - 7 M dexamethasone)
medium. Osteogenic differentiation is shown by (A) alkaline phosphatase (ALP) activity and (B) Runx-2 expression in control
and differentiated cells (western blot). Relative quantification is shown as mean – standard deviation of 3 different experi-
ments performed on 3 different donors. *c, statistically different from b and a. (C) Leptin expression was measured by ELISA
in supernatant of control and differentiated MSC. *b, statistically different from a. *d, statistically different from c and b. *c,
statistically different from a. (D) ALP and leptin expression in BM-MSC cultured for 2 weeks in the presence of osteogenic
medium supplemented or not with dexamethasone. *b, statistically different from a and c. Color images available online at
www.liebertonline.com/scd
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that the ALK-5 pathway is an inhibitor of leptin expression.
Furthermore, when we inhibited the ALK-5 pathway using
SB431542, leptin expression was significantly increased. In-
terestingly, this increased leptin expression was associated
with increased p-Smad1/5 expression. Finally, silencing
Smad1 expression resulted in leptin expression inhibition,
suggesting that the ALK-1 pathway is a leptin expression
activator. We also showed that prednisolone-induced leptin
expression in BM-MSC, and SVF was accompanied by TGF-
bRII expression up-regulation and p-Smad2 expression
down-regulation. Taken collectively, these results suggest a
model where the signalling balance between both ALK-5 and
ALK-1 can determine leptin expression in response to the
TGF-b pathway (Fig. 5). In this model, glucocorticoid up-
regulates TGF-bRII expression, but at the same time, directs
the TGF-b pathway to signal through ALK-1.
TGF-b1 was also able to inhibit OB-R expression in BM-
MSC, whereas prednisolone up-regulated its expression. In-
terestingly, SB431542 induced OB-R expression and blocked
the inhibitory effect of TGF-b1, suggesting a similar mecha-
nism for OB-R expression as for leptin. The effect of pred-
nisolone on leptin expression in BM-MSC was not observed
in UMSC. UMSC have functional glucocorticoid receptors, as
demonstrated by decreased interleukin-6 production after
prednisolone treatment (data not shown). Contrary to BM-
MSC, UMSC have a constitutive increased p-Smad2 expres-
sion that is not modulated by glucocorticoids. In addition,
despite having the same ALK-1 and ALK-5 expression pat-
tern as BM-MSC, UMSC were not able to show any leptin
expression after SB 431542 treatment (data not shown). The
constitutive p-Smad2 expression in UMSC seems to be in-
dependent of TGF-b receptor stimulation. Such constitutive
activation was described in PPAR-g null mouse embryonic
fibroblasts (MEFs) [20]. However, SB 431542 was able to
abrogate Smad2 phosphorylation in MEFs, whereas SB
431542 treatment did not induce leptin expression in UMSC
(data not shown), suggesting a different mechanism for these
cells. Furthermore, unlike BM-MSC and SVF, UMSC did not
show any increased TGF-bRII expression in the presence of
prednisolone.
It was shown that the gene expression pattern of BM-MSC
is more similar to osteoblasts, suggesting a better osteogenic
potential. In contrast, UMSCs are more primitive, because
they share more common genes with embryonic stem cells
[21]. In the present study, we showed a better osteogenic
potential with SVF and BM-MSC than with UMSC. This
differential osteogenic potential was correlated to leptin ex-
pression in these cells. Leptin is now admitted to be impli-
cated in osteogenic differentiation [1,2]. This suggests that
the difference in osteogenic potential between SVF, BM-
MSC, and UMSC could be attributed to their different leptin
expression potential.
Multiple myeloma (MM) expands almost exclusively in the
BM and generates devastating bone lesions, in which bone
formation is impaired. Takeuchi k et al. attributed this ter-
minal osteoblastic differentiation impairment in MM to TGF-b
that is abundantly deposited in the bone matrix. Using
SB431542 to inhibit TGF-b action, they potently enhanced
osteoblast differentiation from BM stromal cells [22]. Since
leptin is implicated in osteogenic differentiation [23], the effect
attributed by Takeuchi k et al. to TGF-b signalling inhibition
in MM could be mediated through leptin expression.
Leptin is considered a pro-inflammatory peptide in rheu-
matic diseases, whereas it is not expressed in healthy cartilage
[24,25]. Indeed, recent works have shown that leptin inhibits
chondrogenesis [26]. Blaney Davidson et al. showed an in-
creased ALK-1/ALK-5 ratio as a cause of deviant chondrocyte
behavior (elevated MMP-13 expression), which contributes to
age-related cartilage destruction and osteoarthritis in humans
[27,28]. Our results suggest that leptin may be one of the as-
pects of aberrant chondrocytes differentiation that results from
changes in TGF-b signalling related to age or osteoarthritis.
In this work, we showed the involvement of ALK-1/ALK-
5 pathways for leptin expression in MSC. The field of cell
FIG. 5. The balance in sig-
nalling through either ALK-1
or ALK-5 regulates leptin ex-
pression in MSC. TGFb1 was
shown to signal by the ALK-
5-Smad2/3 pathway and/or
the ALK-1-Smad1/5 path-
way [18]. When TGFb1 binds
to TGFbRII, it induces the
activation of both ALK-1 and
ALK-5 pathways, with a
predominance of the inhibi-
tory ALK-5-Smad-2 route.
However, the inhibition of
ALK-5 favors the activator
ALK-1 route, leading to in-
creased leptin expression.
In the presence of predniso-
lone, TGFbRII expression is




favored, thereby leading to
amplified leptin expression.
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therapy is experiencing more and more cell types for dif-
ferent protocols that do not necessarily share the same re-
quirement in term of protein expression. Leptin is now
admitted to be strongly implicated in osteogenic differenti-
ation [1]. Thus, in osteogenic protocols, the use of naturally
leptin MSC producer, such as SVF or BM-MSC, could be
more appropriated than UMSC. On thecontrary, since heal-
thy chondrocytes do not express leptin, the use of MSC in
protocols of cartilage disorders repair would better require a
leptin nonproducer MSC such as UMSC.
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